These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1474171)

  • 21. Pharmacokinetic difference between S-(+)- and R-(-)-etodolac in rats.
    Shi JM; Lai SG; Xu CJ; Duan GL; Li D
    Acta Pharmacol Sin; 2004 Aug; 25(8):996-9. PubMed ID: 15301730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers.
    Wong SL; Awni WM; Cavanaugh JH; el-Shourbagy T; Locke CS; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():9-21. PubMed ID: 8620676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic profile of etodolac in special populations.
    Benet LZ
    Eur J Rheumatol Inflamm; 1994; 14(1):15-8. PubMed ID: 7744123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
    Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G
    Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereoselective pharmacokinetics of oxprenolol and its glucuronides in humans.
    Laethem ME; Lefebvre RA; Belpaire FM; Vanhoe HL; Bogaert MG
    Clin Pharmacol Ther; 1995 Apr; 57(4):419-24. PubMed ID: 7712670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enantioselective analysis of etodolac in human plasma by LC-MS/MS: Application to clinical pharmacokinetics.
    de Miranda Silva C; Rocha A; Tozatto E; da Silva LM; Donadi EA; Lanchote VL
    J Pharm Biomed Anal; 2016 Feb; 120():120-6. PubMed ID: 26723001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of the enantiomers of acenocoumarol in man.
    Godbillon J; Richard J; Gerardin A; Meinertz T; Kasper W; Jähnchen E
    Br J Clin Pharmacol; 1981 Nov; 12(5):621-9. PubMed ID: 7332726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of flurbiprofen, ketoprofen and etodolac enantiomers by pre-column derivatization RP-HPLC and application to drug-protein binding in human plasma.
    Jin YX; Tang YH; Zeng S
    J Pharm Biomed Anal; 2008 Apr; 46(5):953-8. PubMed ID: 18329215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profile of etodolac: pharmacokinetic evaluation in special populations.
    Brater DC; Lasseter KC
    Clin Rheumatol; 1989 Mar; 8 Suppl 1():25-35. PubMed ID: 2525981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioavailability and bioequivalence of two formulations of etodolac (tablets and suppositories).
    Molina-Martinez IT; Herrero R; Gutiérrez JA; Iglesias JM; Fábregas JL; Martinez-Tobed A; Cadorniga R
    J Pharm Sci; 1993 Feb; 82(2):211-3. PubMed ID: 8445537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Albumin binding sites for etodolac enantiomers.
    Mignot I; Presle N; Lapicque F; Monot C; Dropsy R; Netter P
    Chirality; 1996; 8(3):271-80. PubMed ID: 8777148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic modeling and simulation of etodolac following single oral administration in dogs.
    Baek IH
    Xenobiotica; 2019 Aug; 49(8):981-986. PubMed ID: 30216103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of vigabatrin: implications of creatinine clearance.
    Haegele KD; Huebert ND; Ebel M; Tell GP; Schechter PJ
    Clin Pharmacol Ther; 1988 Nov; 44(5):558-65. PubMed ID: 3180638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses.
    Foster RT; Jamali F; Russell AS; Alballa SR
    J Pharm Sci; 1988 Jan; 77(1):70-3. PubMed ID: 3346825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of sotalol enantiomers in humans.
    Carr RA; Foster RT; Lewanczuk RZ; Hamilton PG
    J Clin Pharmacol; 1992 Dec; 32(12):1105-9. PubMed ID: 1487548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac.
    de Miranda Silva C; Rocha A; Tozatto E; da Silva LM; Donadi EA; Dalla Costa T; Lanchote VL; Schmidt S; Bulitta JB
    AAPS J; 2017 Nov; 19(6):1814-1825. PubMed ID: 28875479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of the route of administration on the pharmacokinetics of pirprofen enantiomers in the rat.
    Brocks DR; Liang WT; Jamali F
    Chirality; 1993; 5(2):61-4. PubMed ID: 8343343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacokinetics of ketoprofen and its enantiomers.
    Jamali F; Brocks DR
    Clin Pharmacokinet; 1990 Sep; 19(3):197-217. PubMed ID: 2203580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of severity of chronic inflammatory joint disease on the pharmacokinetics of indomethacin and etodolac.
    Pawlotsky Y; Le Dantec P; Jacquelinet C; Lapicque F; Goasguen J; Perdriger A; Veillard E; Guggenbuhl P; Netter P
    Rev Rhum Engl Ed; 1996 Mar; 63(3):179-87. PubMed ID: 8731235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age and gender influence the stereoselective pharmacokinetics of propranolol.
    Gilmore DA; Gal J; Gerber JG; Nies AS
    J Pharmacol Exp Ther; 1992 Jun; 261(3):1181-6. PubMed ID: 1602383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.